We are a development stage biopharmaceutical company utilizing patented technology to develop longer-acting, proprietary versions of already-approved therapeutic proteins that currently generate billions of dollars in annual global sales. We have obtained certain exclusive worldwide rights from Washington University in St. Louis, Missouri to use a short, naturally-occurring amino acid sequence (peptide) that has the effect of slowing the removal from the body of the therapeutic protein to which it is attached. This Carboxyl Terminal Peptide (CTP) can be readily attached to a wide array of existing therapeutic proteins, stabilizing the therapeutic protein in the bloodstream and extending its life span without additional toxicity or loss of desired biological activity. We are using the CTP technology to develop new, proprietary versions of certain existing therapeutic proteins that have longer life spans than therapeutic proteins without CTP. We believe that our products will have greatly improved therapeutic profiles and distinct market advantages.
Company profile
Ticker
PBTH
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LDG Inc, Modigene Inc.
SEC CIK
Corporate docs
Latest filings (excl ownership)
15-12B
Securities registration termination
26 Sep 13
EFFECT
Notice of effectiveness
9 Sep 13
POS AM
Prospectus update (post-effective amendment)
6 Sep 13
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Sep 13
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Sep 13
25-NSE
Exchange delisting
30 Aug 13
8-K
Completion of Acquisition or Disposition of Assets
30 Aug 13
10-Q
2013 Q2
Quarterly report
9 Aug 13
DEFM14A
Proxy related to merger
24 Jul 13
PRER14A
Preliminary revised proxy
16 Jul 13